256 related articles for article (PubMed ID: 25781640)
1. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
2. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
3. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
[TBL] [Abstract][Full Text] [Related]
4. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma.
Zhu X; Zou S; Zhou J; Zhu H; Zhang S; Shang Z; Ding WQ; Wu J; Chen Y
Oncol Rep; 2016 Mar; 35(3):1664-70. PubMed ID: 26752104
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.
Yang F; Guo L; Cao Y; Li S; Li J; Liu M
Med Sci Monit; 2018 Sep; 24():6506-6516. PubMed ID: 30219819
[TBL] [Abstract][Full Text] [Related]
7. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
Shehata M; Shehata M; Shehata F; Pater A
Cell Biol Int; 2004; 28(12):895-904. PubMed ID: 15566959
[TBL] [Abstract][Full Text] [Related]
8. Bag-1L is a stress-withstand molecule prevents the downregulation of Mcl-1 and c-Raf under control of heat shock proteins in cisplatin treated HeLa cervix cancer cells.
Ozfiliz P; Arisan ED; Coker-Gurkan A; Obakan P; Eralp TN; Dinler-Doganay G; Palavan-Unsal N
Asian Pac J Cancer Prev; 2014; 15(11):4475-82. PubMed ID: 24969872
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the reversal effect of mifepristone on drug resistance of the human cervical cancer cell line HeLa/MMC.
Chen H; Duan J; Zuo F
Genet Mol Res; 2014 Feb; 13(1):1288-95. PubMed ID: 24634186
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
11. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
12. Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy.
Okamoto E; Sumi T; Misugi F; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Jan; 15(1):41-7. PubMed ID: 15583826
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the BRIP1 ameliorates chemosensitivity to cisplatin by inhibiting Rac1 GTPase activity in cervical carcinoma HeLa cells.
Liu Y; Li H; Zhang R; Dang H; Sun P; Zou L; Zhang Y; Gao Y; Hu Y
Gene; 2016 Mar; 578(1):85-91. PubMed ID: 26680099
[TBL] [Abstract][Full Text] [Related]
15. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel.
Mao BD; Xu P; Xu P; Zhong Y; Ding WW; Meng QZ
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180057
[TBL] [Abstract][Full Text] [Related]
16. Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.
Kong L; Murata MM; Digman MA
Biochem Biophys Res Commun; 2018 Jan; 496(1):199-204. PubMed ID: 29307819
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of oxidored-nitro domain containing protein 1 inhibits human nasopharyngeal carcinoma and cervical cancer cell proliferation and induces apoptosis: Involvement of mitochondrial apoptotic pathways.
Ouyang J; Wu M; Huang C; Cao L; Li G
Oncol Rep; 2013 Jan; 29(1):79-86. PubMed ID: 23124592
[TBL] [Abstract][Full Text] [Related]
18. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C β inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin.
Li N; Zhang W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28246354
[TBL] [Abstract][Full Text] [Related]
20. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility.
Zhang S; Chen H; Zhao X; Cao J; Tong J; Lu J; Wu W; Shen H; Wei Q; Lu D
Oncogene; 2013 Jan; 32(2):242-50. PubMed ID: 22349819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
